Engineering of CRISPR-Cas12b for human genome editing
Article 2019 en
Authors
JS
Jonathan Strecker
SJ
Sara R. Jones
BK
Balwina Koopal
Abstract
1 min read
Abstract The type-V CRISPR effector Cas12b (formerly known as C2c1) has been challenging to develop for genome editing in human cells, at least in part due to the high temperature requirement of the characterized family members. Here we explore the diversity of the Cas12b family and identify a promising candidate for human gene editing from Bacillus hisashii , BhCas12b. However, at 37 °C, wild-type BhCas12b preferentially nicks the non-target DNA strand instead of forming a double strand break, leading to lower editing efficiency. Using a combination of approaches, we identify gain-of-function mutations for BhCas12b that overcome this limitation. Mutant BhCas12b facilitates robust genome editing in human cell lines and ex vivo in primary human T cells, and exhibits greater specificity compared to S. pyogenes Cas9. This work establishes a third RNA-guided nuclease platform, in addition to Cas9 and Cpf1/Cas12a, for genome editing in human cells.
Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian M. Slaymaker, Kira S. Makarova, Patrick Essletzbichler, Sara E. Volz, Julia Joung, John van der Oost, Aviv Regev, Eugene V Koonin, Feng Zhang
F. Ann Ran, Le Cong, Winston X. Yan, David A. Scott, Jonathan S. Gootenberg, Andrea J. Kriz, Bernd Zetsche, Ophir Shalem, Xuebing Wu, Kira S. Makarova, Eugene V Koonin, Phillip A. Sharp, Feng Zhang
Benedetta Artegiani, Delilah Hendriks, Joep Beumer, Rutger N.U. Kok, Xuan Zheng, Indi P. Joore, Susana M. Chuva de Sousa Lopes, Jeroen S. van Zon, Sander J. Tans, Hans Clevers
Discussion(0)
No comments yet. Be the first to comment.